more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$88.82 USD

+0.53 (0.60%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $88.74 -0.08 (-0.09%) 4:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

3 Biotech Stocks With Rising Estimates in the Past Month

by Zacks Equity Research Published on September 28,2018

The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.

Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch

by Ryan McQueeney Published on September 27,2018

Ryan McQueeney highlights the Fed's latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond's earnings results and touches on analyst research related to Apple. Later, he is joined by Zacks' biotech guru, Kevin Cook, to chat about CRISPR stocks and how to invest in the developing science.

Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion

by Zacks Equity Research Published on September 27,2018

Alexion (ALXN) will acquire clinical-stage biotech company, Syntimmune for $1.2 billion to augment its rare disease pipeline.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research Published on September 26,2018

In the latest trading session, Gilead Sciences (GILD) closed at $75.65, marking a +0.81% move from the previous day.

GILDPositive Net Change

Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars

by Zacks Equity Research Published on September 26,2018

Data read-outs by quite a few companies grabbed headlines in the biotech sector this week.

Gilead (GILD) to Launch Generics for Leading HCV Treatments

by Zacks Equity Research Published on September 25,2018

Given the persistent decline in HCV sales, Gilead (GILD) plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments, Epclusa and Harvoni.

Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx

by Zacks Equity Research Published on September 24,2018

Exelixis, Inc. (EXEL) and partner Ipsen get a positive opinion from the CHMP for Cabometyx tablets as a monotherapy for the second-line treatment of hepatocellular carcinoma in adults.

CHMP Reconfirms Negative Opinion for Sarepta's Exondys

by Zacks Equity Research Published on September 24,2018

The CHMP re-confirmed the negative opinion for Sarepta's (SRPT) Exondys, which is developed to treat individuals who have a specific type of Duchenne muscular dystrophy.

Rubius (RUBY) in Focus: Stock Moves 8.7% Higher

by Zacks Equity Research Published on September 24,2018

Rubius (RUBY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

FDA Confirms Positive Safety Profile of Acadia's Nuplazid

by Zacks Equity Research Published on September 21,2018

Acadia's shares soar more than 20% as the FDA issues a statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson's disease psychosis.

Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada

by Zacks Equity Research Published on September 20,2018

Exelixis (EXEL) and partner Ipsen Biopharmaceuticals Canada gain approval for Cabometyx from Health Canada for the treatment of advanced renal cell carcinoma in adult patients.

Ultragenyx's Shares Surge More Than 80% in the Year So Far

by Zacks Equity Research Published on September 20,2018

Ultragenyx's (RARE) share price has increased by about 85.2% year to date based on some positive developments for the product candidates of the company.

Molecular Templates Surges 50%, Inks Cancer Deal With Takeda

by Zacks Equity Research Published on September 20,2018

Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.